Winslow Evans & Crocker’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-1,402
Closed -$4K 1198
2019
Q4
$4K Hold
1,402
﹤0.01% 1066
2019
Q3
$4K Hold
1,402
﹤0.01% 1055
2019
Q2
$4K Sell
1,402
-1,402
-50% -$700 ﹤0.01% 1055
2019
Q1
$8K Hold
2,804
﹤0.01% 909
2018
Q4
$8K Hold
2,804
﹤0.01% 852
2018
Q3
$8K Hold
2,804
﹤0.01% 876
2018
Q2
$8K Buy
2,804
+1,402
+100% +$653 ﹤0.01% 879
2018
Q1
$596 Hold
1,402
﹤0.01% 1090
2017
Q4
$534 Hold
1,402
﹤0.01% 1097
2017
Q3
$506 Sell
1,402
-14
-1% -$5 ﹤0.01% 1088
2017
Q2
$538 Hold
1,416
﹤0.01% 1233
2017
Q1
$638 Buy
1,416
+40
+3% +$18 ﹤0.01% 1201
2016
Q4
$524 Hold
1,376
﹤0.01% 1212
2016
Q3
$372 Hold
1,376
﹤0.01% 1262
2016
Q2
$332 Hold
1,376
﹤0.01% 1252
2016
Q1
$157 Hold
1,376
﹤0.01% 1267
2015
Q4
$158 Hold
1,376
﹤0.01% 1349
2015
Q3
$264 Hold
1,376
﹤0.01% 1268
2015
Q2
$964 Hold
1,376
﹤0.01% 1242
2015
Q1
$934 Hold
1,376
﹤0.01% 1218
2014
Q4
$1.09K Hold
1,376
﹤0.01% 1229
2014
Q3
$640 Buy
1,376
+850
+162% +$412 ﹤0.01% 1341
2014
Q2
$263 Hold
526
﹤0.01% 1273
2014
Q1
$163 Hold
526
﹤0.01% 1265
2013
Q4
$0 Buy
+526
New +$636 ﹤0.01% 1427

Winslow Evans & Crocker's GCVRZ Position: Q1 2020 in Review

Winslow Evans & Crocker sold out of Sanofi Contingent Value Rights (GCVRZ) in Q1 2020, closing a stake of 1,402 shares — an estimated $4K sold.

Winslow Evans & Crocker first reported a position in GCVRZ in Q4 2013 and held it in 25 quarters. The position peaked at $8K in Q1 2019. 2 funds tracked by Wall St. Rank hold GCVRZ as of Q1 2020.

  • Winslow Evans & Crocker reported no remaining Sanofi Contingent Value Rights position as of Q1 2020 after selling out during the quarter.
  • Winslow Evans & Crocker sold 1,402 Sanofi Contingent Value Rights shares in Q1 2020, an estimated $4K.
  • Winslow Evans & Crocker first reported a position in Sanofi Contingent Value Rights in Q4 2013 and held it in 25 quarters.
  • Winslow Evans & Crocker's Sanofi Contingent Value Rights position peaked at $8K in Q1 2019.
  • 2 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q1 2020.

Based on Winslow Evans & Crocker's 13F filing for Q1 2020, filed 20 Apr 2020.